nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—Pruritus—Mechlorethamine—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Degarelix—Hypotension—Teniposide—lymphatic system cancer	0.00413	0.00413	CcSEcCtD
Degarelix—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Degarelix—Abscess—Methotrexate—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Degarelix—Arthralgia—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Degarelix—Discomfort—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Degarelix—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Degarelix—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Degarelix—Dyspnoea—Teniposide—lymphatic system cancer	0.00394	0.00394	CcSEcCtD
Degarelix—Dysuria—Vincristine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Degarelix—Depression—Carmustine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Degarelix—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Degarelix—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Degarelix—Decreased appetite—Teniposide—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Degarelix—Renal failure—Carmustine—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Degarelix—Vomiting—Mechlorethamine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Degarelix—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00381	0.00381	CcSEcCtD
Degarelix—Urinary tract infection—Carmustine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Degarelix—Rash—Mechlorethamine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Degarelix—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Degarelix—Weight decreased—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Degarelix—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Degarelix—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Degarelix—Depression—Vincristine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Degarelix—Weight increased—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Degarelix—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Degarelix—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Degarelix—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Degarelix—Myocardial infarction—Vincristine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Degarelix—Feeling abnormal—Teniposide—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Degarelix—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Degarelix—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Degarelix—Chills—Bleomycin—lymphatic system cancer	0.0036	0.0036	CcSEcCtD
Degarelix—Bone disorder—Methotrexate—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Degarelix—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Degarelix—Renal failure—Mitoxantrone—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Degarelix—Nausea—Mechlorethamine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Degarelix—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Degarelix—Alopecia—Bleomycin—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Degarelix—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Degarelix—Urticaria—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Degarelix—Body temperature increased—Teniposide—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Degarelix—Abdominal pain—Teniposide—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Degarelix—Erythema—Bleomycin—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Degarelix—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Degarelix—Dyspnoea—Fludarabine—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Degarelix—Oedema peripheral—Carmustine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Degarelix—Decreased appetite—Fludarabine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Degarelix—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Degarelix—Fatigue—Fludarabine—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Degarelix—Inflammation—Methotrexate—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Degarelix—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Degarelix—Pain—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Degarelix—Constipation—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Degarelix—Urinary tract disorder—Vincristine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Degarelix—Urethral disorder—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Degarelix—Eye disorder—Carmustine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Degarelix—Hypersensitivity—Teniposide—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Degarelix—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Degarelix—Anaemia—Bleomycin—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Degarelix—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Degarelix—Asthenia—Teniposide—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Degarelix—Malaise—Bleomycin—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Degarelix—Pruritus—Teniposide—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Degarelix—Arrhythmia—Carmustine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Degarelix—Cardiac disorder—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Degarelix—Alopecia—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Degarelix—Body temperature increased—Fludarabine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Degarelix—Mental disorder—Carmustine—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Degarelix—Malnutrition—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Degarelix—Erythema—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Degarelix—Angiopathy—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Degarelix—Diarrhoea—Teniposide—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Degarelix—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Degarelix—Alopecia—Vincristine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Degarelix—Back pain—Carmustine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Degarelix—Discomfort—Bleomycin—lymphatic system cancer	0.00294	0.00294	CcSEcCtD
Degarelix—Mental disorder—Vincristine—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Degarelix—Chills—Mitoxantrone—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Degarelix—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Degarelix—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Degarelix—Alopecia—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Degarelix—Vision blurred—Carmustine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Degarelix—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Degarelix—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Degarelix—Erythema—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Degarelix—Anaemia—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Degarelix—Back pain—Vincristine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Degarelix—Vomiting—Teniposide—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Degarelix—Asthenia—Fludarabine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Degarelix—Rash—Teniposide—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Degarelix—Dermatitis—Teniposide—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Degarelix—Headache—Teniposide—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Degarelix—Pruritus—Fludarabine—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Degarelix—Back pain—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Degarelix—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Degarelix—Anaemia—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Degarelix—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Degarelix—Hypotension—Bleomycin—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Degarelix—Diarrhoea—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Degarelix—Hypertension—Carmustine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Degarelix—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Degarelix—Nausea—Teniposide—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Degarelix—Anaemia—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Degarelix—Malaise—Mitoxantrone—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Degarelix—Dyspnoea—Bleomycin—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Degarelix—Hypertension—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Degarelix—Decreased appetite—Bleomycin—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Degarelix—Vomiting—Fludarabine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Degarelix—Rash—Fludarabine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Degarelix—Dermatitis—Fludarabine—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Degarelix—Hypertension—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Degarelix—Pain—Bleomycin—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Degarelix—Headache—Fludarabine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Degarelix—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Degarelix—Discomfort—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Degarelix—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Degarelix—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Degarelix—Nervous system disorder—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Degarelix—Hypotension—Carmustine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Degarelix—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Degarelix—Nausea—Fludarabine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Degarelix—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Degarelix—Urticaria—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Degarelix—Body temperature increased—Bleomycin—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Degarelix—Insomnia—Carmustine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Degarelix—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Degarelix—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Degarelix—Hypotension—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Degarelix—Dyspnoea—Carmustine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Degarelix—Decreased appetite—Carmustine—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Degarelix—Hypotension—Mitoxantrone—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Degarelix—Insomnia—Vincristine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Degarelix—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Degarelix—Constipation—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Degarelix—Pain—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Degarelix—Breast disorder—Methotrexate—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Degarelix—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Degarelix—Decreased appetite—Vincristine—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Degarelix—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Degarelix—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Degarelix—Feeling abnormal—Carmustine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Degarelix—Fatigue—Vincristine—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Degarelix—Asthenia—Bleomycin—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Degarelix—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Constipation—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Pain—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Degarelix—Pruritus—Bleomycin—lymphatic system cancer	0.00202	0.00202	CcSEcCtD
Degarelix—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Degarelix—Fatigue—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Degarelix—Pain—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Degarelix—Constipation—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Degarelix—Body temperature increased—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Degarelix—Abdominal pain—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Degarelix—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Degarelix—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Degarelix—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Degarelix—Dysuria—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Degarelix—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Degarelix—Abdominal pain—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Degarelix—Body temperature increased—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Degarelix—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Degarelix—Urticaria—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Degarelix—Hypersensitivity—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Degarelix—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Degarelix—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Degarelix—Vomiting—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Degarelix—Depression—Methotrexate—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Degarelix—Rash—Bleomycin—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Degarelix—Dermatitis—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Degarelix—Asthenia—Carmustine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Degarelix—Renal failure—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Degarelix—Hypersensitivity—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Degarelix—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Degarelix—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Degarelix—Asthenia—Vincristine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Degarelix—Diarrhoea—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Degarelix—Nausea—Bleomycin—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Degarelix—Asthenia—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Degarelix—Dizziness—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Degarelix—Diarrhoea—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Degarelix—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Degarelix—Urethral disorder—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Degarelix—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Degarelix—Vomiting—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Degarelix—Dizziness—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Rash—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Dermatitis—Carmustine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Degarelix—Headache—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Degarelix—Vomiting—Vincristine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Degarelix—Cardiac disorder—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Degarelix—Rash—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Degarelix—Dermatitis—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Degarelix—Headache—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Degarelix—Nausea—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Degarelix—Angiopathy—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Degarelix—Vomiting—Mitoxantrone—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Degarelix—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Degarelix—Rash—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Degarelix—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Degarelix—Chills—Methotrexate—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Degarelix—Headache—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Degarelix—Alopecia—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Degarelix—Erythema—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Degarelix—Nausea—Vincristine—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Degarelix—Nausea—Mitoxantrone—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Degarelix—Back pain—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Degarelix—Anaemia—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Degarelix—Malaise—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Degarelix—Arthralgia—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Discomfort—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Degarelix—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Degarelix—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Degarelix—Hypotension—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Degarelix—Insomnia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—lymphatic system cancer	0.001	0.001	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000994	0.000994	CcSEcCtD
Degarelix—Fatigue—Methotrexate—lymphatic system cancer	0.000993	0.000993	CcSEcCtD
Degarelix—Pain—Methotrexate—lymphatic system cancer	0.000985	0.000985	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000949	0.000949	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000942	0.000942	CcSEcCtD
Degarelix—Urticaria—Methotrexate—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—lymphatic system cancer	0.00091	0.00091	CcSEcCtD
Degarelix—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000848	0.000848	CcSEcCtD
Degarelix—Asthenia—Methotrexate—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Degarelix—Pruritus—Methotrexate—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—lymphatic system cancer	0.000788	0.000788	CcSEcCtD
Degarelix—Dizziness—Methotrexate—lymphatic system cancer	0.000761	0.000761	CcSEcCtD
Degarelix—Vomiting—Methotrexate—lymphatic system cancer	0.000732	0.000732	CcSEcCtD
Degarelix—Rash—Methotrexate—lymphatic system cancer	0.000726	0.000726	CcSEcCtD
Degarelix—Dermatitis—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Degarelix—Headache—Methotrexate—lymphatic system cancer	0.000721	0.000721	CcSEcCtD
Degarelix—Nausea—Methotrexate—lymphatic system cancer	0.000684	0.000684	CcSEcCtD
